7 Quotes by John McCamant

That would make for a much quicker response to a flu outbreak, and would help move vaccine technology into the 21st century. Right now vaccine technology is in the middle of the 20th century. It just doesn't make sense to rely on outdated methods that have been around 40 years.

The Swiss are much smarter than American pharmaceutical firms.

The space is getting full. When floating paper for a company without earnings, it's harder to sell a promise. People have a harder time to say this glass is full unless they feel good about the markets in general.

This is rather large. The fact that Monsanto did it right in front of a trial, they (the university) must have had a lock-shut case.

A major wild card that has yet to really surface is legislation that allows U.S. corporations to repatriate foreign earnings at a 5.25 percent tax rate instead of 35 percent. To be eligible the money has to be repatriated in 2005 and reinvested by Dec. 31, 2007. While the money cannot be used for many corporate activities, it can be used for mergers and acquisition.

They definitely had sex appeal and make a good story, but they didn't make any money. When the rubber hits the road, if you're not delivering it is hard to go out and get investors.

The FDA will be asking the toughest questions you can imagine and the investment community will be on pins and needles to find out what the agency wants.